Previous 10 | Next 10 |
2024-04-16 14:00:02 ET Edward White from H.C. Wainwright issued a price target of $29.00 for CGEM on 2024-04-16 11:53:00. The adjusted price target was set to $29.00. At the time of the announcement, CGEM was trading at $17.625. The overall price target consensus is at $...
Shares of Cullinan Oncology, Inc. (NASDAQ: CGEM) traded at a new 52-week high today and are currently trading at $19.91. So far today, approximately 771.44k shares have been exchanged, as compared to an average 30-day volume of 277.78k shares. Cullinan Oncology Inc., a biopharmaceutical compa...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 37.1% to $0.1629 on volume of 102,747,129 shares WiSA Technologies Inc. (WISA) rose 69.1% to $2.96 on volume of 24,734,833 shares Peraso Inc. (PRSO) rose 37.0% to $1.7393 on volume of 23,546,162 shares ...
2024-04-16 10:00:22 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Shor...
2024-04-16 08:45:14 ET More on premarkets gainers and stock WiSA Technologies to effect 1-for-150 reverse stock split WiSA Technologies drops 5%, accepts Nasdaq compliance plan Seeking Alpha’s Quant Rating on Avalo Therapeutics Historical earnings data...
2024-04-16 07:33:20 ET More on Cullinan Oncology Cullinan Therapeutics gets $280M via oversubscribed private placement Seeking Alpha’s Quant Rating on Cullinan Oncology Historical earnings data for Cullinan Oncology Financial information for Cullinan O...
2024-04-16 07:05:57 ET More on Cullinan Oncology Seeking Alpha’s Quant Rating on Cullinan Oncology Historical earnings data for Cullinan Oncology Financial information for Cullinan Oncology Read the full article on Seeking Alpha For further det...
CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication Clinical observations from CLN-978 B-NHL study show rapid, deep, and sustained B cell depletion and clinical activity Corporate name change to Cu...
Financing includes new and existing leading life sciences institutional investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 Cullinan to host a virtual investor event on April 16 at 8:00 am ET CAMBRIDGE, Mass., Apr...
2024-03-31 12:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Cullinan Oncology Inc. Company Name:
CGEM Stock Symbol:
OTCMKTS Market:
Cullinan Oncology Inc. Website:
2024-06-30 11:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc . (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in patients receiving zipalertinib after prior treatment with amivanta...
2024-05-29 21:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...